13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001643354
Total reported value
$20.9M
$20.9M
31 檔
728.6%
In Q1 2024, Lion Point Capital, LP's U.S. equity holdings reached a combined market value of $20.9M, distributed across 31 disclosed stock positions.
During Q1 2024, Lion Point Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SMTC | Semtech CORP | Stock-Tech | 38.40% | — | -50.77% | |
| 2 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 29.09% | — | +50.00% | |
| 3 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 10.71% | — | -0.71% | |
| 4 | ARDX | Ardelyx Inc | Stock-Other | 4.27% | -1.47% | -9.12% | |
| 5 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.65% | — | — | |
| 6 | MIST | Milestone Pharmaceuticals In | Stock-Other | 2.30% | -0.57% | +39.39% | |
| 7 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.44% | — | — | |
| 8 | GERN | Geron CORP | Stock-Other | 1.11% | -1.61% | — | |
| 9 | INSM | Insmed Inc | Stock-Healthcare | 1.07% | — | — | |
| 10 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 1.06% | +1.65% | +54.55% | |
| 11 | 0LS | Burgerfi International Inc | Stock-Other | 0.89% | — | — | |
| 12 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.86% | -1.27% | +88.41% | |
| 13 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 0.78% | — | +3.13% | |
| 14 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.63% | — | +233.33% | |
| 15 | ✓ | Stock-Other | 0.61% | — | +59.67% | ||
| 16 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.58% | — | — | |
| 17 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.53% | -1.50% | — | |
| 18 | ✓ | Enphys Acquisition CORP | Stock-Other | 0.47% | — | — | |
| 19 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.43% | -0.34% | — | |
| 20 | HUMA | Humacyte Inc | Stock-Other | 0.41% | +0.07% | — | |
| 21 | RGNX | Regenxbio Inc | Stock-Other | 0.38% | +0.19% | — | |
| 22 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.35% | — | — | |
| 23 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 24 | REPL | Replimune Group Inc | Stock-Other | 0.19% | — | — | |
| 25 | MCRB1EUR | Seres Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 26 | 4NX1 | Lumos Pharma Inc | Stock-Other | 0.14% | — | — | |
| 27 | BATL | Battalion Oil CORP | Stock-Other | 0.06% | — | -91.03% | |
| 28 | ✓ | Burgerfi International Inc | Stock-Other | 0.05% | — | — | |
| 29 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.03% | — | — | |
| 30 | MSFT | Microsoft CORP | Stock-Tech | 0.02% | — | — | |
| 31 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 0.01% | — | — |
According to official SEC Form 13F filings, Lion Point Capital, LP reported a total U.S. public equity portfolio value of $20.9M across 31 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SMTC, IWM, MRNS*) accounted for 728.6% of total reported equity market value during Q1 2024.
During Q1 2024, Lion Point Capital, LP's top holdings by market value included SMTC (38.4%)、IWM (29.1%)、MRNS* (10.7%). The largest single position, SMTC, represented 38.4% of total portfolio value.
In Q1 2024, Lion Point Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.